Impact of H1 Antihistamines on Bacillus Calmette-Guérin–treated Non–muscle-invasive Bladder Cancer
The treatment for non-muscle-invasive bladder cancer (NMIBC) typically includes a solution of BCG (bacillus Calmette-Guérin) instilled into the bladder. We found better survival outcomes (overall survival, cancer-specific survival, recurrence-free survival, and progression-free survival) for patients who took a H1 antihistamine during their BCG treatment for intermediate-risk or high-risk NMIBC. More research is needed to confirm our results.
Authors
- Alex Qinyang Liu (ORCID: https://orcid.org/0000-0003-0302-0472)
- Peter Ka‐Fung Chiu (ORCID: https://orcid.org/0000-0002-1499-8372)
- Jeremy Yuen‐Chun Teoh (ORCID: https://orcid.org/0000-0002-9361-2342)
- Chi‐Fai Ng (ORCID: https://orcid.org/0000-0002-1723-9646)
- Kang Liu (ORCID: https://orcid.org/0000-0001-7929-6534)
- Chris Ho-Ming Wong
- Hongda Zhao
Institutions
- Chinese University of Hong Kong (HK)
- Chinese University of Hong Kong, Shenzhen (CN)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.euros.2025.11.001
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00